Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor 'What This Means' Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase ('POC 1') where clinically meaningful pain reduction was demonstrated
Outlines Company's plans to initiate market expansion study ('POC 2') into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025
Access the 'What This Means' video here
THE WOODLANDS, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ('Autonomix' or the 'Company'), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it recently participated in a Virtual Investor 'What This Means' segment.
For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company's successfully met initial phase of the first-in-human proof-of-concept trial ('PoC 1') and the advancement to a follow-on phase ('PoC 2') evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.
The 'What This Means' video can be accessed here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Amphenol Corporation Announces Pricing of USD-Denominated Senior Notes Offering
WALLINGFORD, Conn., June 09, 2025--(BUSINESS WIRE)--Amphenol Corporation (NYSE: APH) (the "Company") announced today the pricing of its offering of $750 million aggregate principal amount of senior notes due 2028 (the "USD Notes"). The USD Notes will have an interest rate of 4.375% per annum. The closing of the offering of USD Notes (the "USD Notes Offering") is expected to occur on June 12, 2025, subject to the satisfaction of customary closing conditions. Substantially concurrently with or shortly after the USD Notes Offering, the Company expects to offer, by means of a separate prospectus supplement, euro-denominated notes (the "Euro Notes"). Neither the completion of the USD Notes Offering nor the offering of the Euro Notes (the "Euro Notes Offering") is contingent on the completion of the other. Therefore, it is possible that the USD Notes Offering is completed and the Euro Notes Offering is not completed. The Company intends to use the net proceeds from the USD Notes Offering and the Euro Notes Offering to repay borrowings under the Company's U.S. commercial paper program and for general corporate purposes. Citigroup Global Markets Inc., Mizuho Securities USA LLC and TD Securities (USA) LLC are serving as the joint book-running managers for the USD Notes Offering. The USD Notes are being offered pursuant to the Company's effective shelf registration statement on file with the Securities and Exchange Commission (the "SEC"). A prospectus supplement describing the terms of this offering will be filed with the SEC. Copies of the prospectus supplement and accompanying prospectus for the offering may be obtained from Citigroup Global Markets Inc. toll-free at 1-800-831-9146, Mizuho Securities USA LLC toll-free at 1-866-271-7403 and TD Securities (USA) LLC toll-free at 1-855-495-9846. This press release does not constitute an offer to sell or the solicitation of an offer to buy the USD Notes, nor will there be any sale of the USD Notes, in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer, solicitation or sale of the USD Notes will be made only by means of the prospectus supplement and the accompanying prospectus. About Amphenol Amphenol Corporation is one of the world's largest designers, manufacturers and marketers of electrical, electronic and fiber optic connectors and interconnect systems, antennas, sensors and sensor-based products and coaxial and high-speed specialty cable. Amphenol designs, manufactures and assembles its products at facilities in approximately 40 countries around the world and sells its products through its own global sales force, independent representatives and a global network of electronics distributors. Amphenol has a diversified presence as a leader in high-growth areas of the interconnect market including: Automotive, Commercial Aerospace, Communications Networks, Defense, Industrial, Information Technology and Data Communications and Mobile Devices. For more information, visit Forward-Looking Statements Statements in this press release which are other than historical facts are intended to be "forward-looking statements" within the meaning of the Securities Exchange Act of 1934, as amended, the Private Securities Litigation Reform Act of 1995 and other related laws. While the Company believes such statements are reasonable, the actual results and effects could differ materially from those currently anticipated. Details regarding various significant risks and uncertainties that may affect our operating and financial performance can be found in the Company's latest Annual Report on Form 10-K and the Company's subsequent filings with the Securities and Exchange Commission, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. In providing forward-looking statements, the Company is not undertaking any duty or obligation to update these statements publicly as a result of new information, future events or otherwise, except as required by law. View source version on Contacts Sherri ScribnerVice President, Strategy and Investor Relations203-265-8820IR@
Yahoo
13 minutes ago
- Yahoo
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent
- Composition of matter patent affirmed, provides protection into 2030 - Builds on recent ruling in favor of Acadia for formulation patent expiring in 2038 SAN DIEGO, June 09, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia's litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. In its affirmance, the Appeals Court applied the precedent established in Allergan USA, Inc. v. MSN Laboratories Private Ltd., MSN Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, holding that "a first filed, first-issued, later-expiring claim cannot be invalidated by a later-filed, later-issued, earlier-expiring reference claim having a common priority date." "We are gratified that the U.S. Federal Appeals Court has affirmed the lower court's ruling in favor of our composition of matter patent for NUPLAZID, securing protection into 2030 for this patent, and beyond based on the recent favorable ruling for our formulation patent providing patent protection for NUPLAZID 34 mg capsule formulation into 2038," said Catherine Owen Adams, Chief Executive Officer. "These decisions reinforce our commitment to safeguarding the intellectual property that underpins our innovations in addressing serious, unmet medical needs." This follows the U.S. District Court for the District of Delaware ruling in favor of Acadia regarding its '721 formulation patent for NUPLAZID which ruled in favor of Acadia on both infringement and validity arguments in its formulation patent litigation against Aurobindo Pharma Limited and other ANDA (Abbreviated New Drug Application) filers. About Acadia Pharmaceuticals Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases. For more information, visit us at and follow us on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential," "continue" and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) the impact of the court ruling on our business and our ability to defend ourselves in the future; (ii) the continued patent protection for NUPLAZID; and (iii) the anticipated timing for termination of such protections. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our ability to maintain, protect and enhance our intellectual property; the outcome of other existing and potential future lawsuits challenging our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-Q for the quarter ended March 31, 2025 as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law. View source version on Contacts Investor Contacts: Acadia Pharmaceuticals Kildani(858) 261-2872ir@ Acadia Pharmaceuticals Tieszen(858) 261-2950ir@ Media Contact: Acadia Pharmaceuticals Kazenelson(818) 395-3043media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
18 minutes ago
- Business Wire
Amphenol Corporation Announces Pricing of USD-Denominated Senior Notes Offering
WALLINGFORD, Conn.--(BUSINESS WIRE)--Amphenol Corporation (NYSE: APH) (the 'Company') announced today the pricing of its offering of $750 million aggregate principal amount of senior notes due 2028 (the 'USD Notes'). The USD Notes will have an interest rate of 4.375% per annum. The closing of the offering of USD Notes (the 'USD Notes Offering') is expected to occur on June 12, 2025, subject to the satisfaction of customary closing conditions. Substantially concurrently with or shortly after the USD Notes Offering, the Company expects to offer, by means of a separate prospectus supplement, euro-denominated notes (the 'Euro Notes'). Neither the completion of the USD Notes Offering nor the offering of the Euro Notes (the 'Euro Notes Offering') is contingent on the completion of the other. Therefore, it is possible that the USD Notes Offering is completed and the Euro Notes Offering is not completed. The Company intends to use the net proceeds from the USD Notes Offering and the Euro Notes Offering to repay borrowings under the Company's U.S. commercial paper program and for general corporate purposes. Citigroup Global Markets Inc., Mizuho Securities USA LLC and TD Securities (USA) LLC are serving as the joint book-running managers for the USD Notes Offering. The USD Notes are being offered pursuant to the Company's effective shelf registration statement on file with the Securities and Exchange Commission (the 'SEC'). A prospectus supplement describing the terms of this offering will be filed with the SEC. Copies of the prospectus supplement and accompanying prospectus for the offering may be obtained from Citigroup Global Markets Inc. toll-free at 1-800-831-9146, Mizuho Securities USA LLC toll-free at 1-866-271-7403 and TD Securities (USA) LLC toll-free at 1-855-495-9846. This press release does not constitute an offer to sell or the solicitation of an offer to buy the USD Notes, nor will there be any sale of the USD Notes, in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer, solicitation or sale of the USD Notes will be made only by means of the prospectus supplement and the accompanying prospectus. About Amphenol Amphenol Corporation is one of the world's largest designers, manufacturers and marketers of electrical, electronic and fiber optic connectors and interconnect systems, antennas, sensors and sensor-based products and coaxial and high-speed specialty cable. Amphenol designs, manufactures and assembles its products at facilities in approximately 40 countries around the world and sells its products through its own global sales force, independent representatives and a global network of electronics distributors. Amphenol has a diversified presence as a leader in high-growth areas of the interconnect market including: Automotive, Commercial Aerospace, Communications Networks, Defense, Industrial, Information Technology and Data Communications and Mobile Devices. For more information, visit Forward-Looking Statements Statements in this press release which are other than historical facts are intended to be 'forward-looking statements' within the meaning of the Securities Exchange Act of 1934, as amended, the Private Securities Litigation Reform Act of 1995 and other related laws. While the Company believes such statements are reasonable, the actual results and effects could differ materially from those currently anticipated. Details regarding various significant risks and uncertainties that may affect our operating and financial performance can be found in the Company's latest Annual Report on Form 10-K and the Company's subsequent filings with the Securities and Exchange Commission, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. In providing forward-looking statements, the Company is not undertaking any duty or obligation to update these statements publicly as a result of new information, future events or otherwise, except as required by law.
